Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder (Q35641635)

9 August 2017

1 reference

title

Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

9 August 2017

1 reference

1 reference

1 reference

Joshua Caballero

1

1 reference

9 August 2017

Milap C Nahata

series ordinal

2

1 reference

9 August 2017

language of work or name

1 reference

1 December 2003

1 reference

9 August 2017

published in

Clinical Therapeutics

1 reference

9 August 2017

volume

25

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

3065-3083

1 reference

A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Hyperactive boys almost grown up. I. Psychiatric status

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Impact of low birth weight on attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Genetic basis of attention deficit and hyperactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Alterations in K(+)-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Cardiovascular effects of atomoxetine in children, adolescents, and adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990092-0

7 January 2021

10.1016/S0149-2918(03)90092-0

Identifiers

DOI

1 reference

9 August 2017

1 reference